Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Regeneron Predicts Impending Biosimilar Lucentis Impact On Eylea Brand

Samsung Bioepis Tipped For US Ranibizumab Biosimilar Approval Soon

Executive Summary

Regeneron Pharmaceuticals has spoken out on the implication of impending competition to Lucentis for its rival product Eylea, as the market for biosimilar Lucentis looks to form by the close of this year.

You may also be interested in...



Coherus Awaits August 2022 Date As FDA Accepts Ranibizumab Biosimilar

The US FDA has accepted for review the CHS-201 Lucentis biosimilar product developed by Formycon/Bioeq that is to be sold in the US by Coherus BioSciences, shortly after approving the first ranibizumab biosimilar to treat wet age-related macular degeneration.

FDA Approves First Ophthalmic Biosimilar With Samsung Bioepis’ Lucentis Rival

Samsung Bioepis has celebrated the FDA’s first ever approval of an ophthalmic biosimilar with its endorsement of the firm’s Byooviz ranibizumab rival to Lucentis. The firm has also signaled a surprising expected launch date in the US, as well as offering expectations for launch in Europe where the biosimilar was also recently approved.

Samsung Bioepis Boasts Positive Data On Lucentis And Herceptin Biosimilars

Ahead of launching potentially its Lucentis biosimilar in the EU early next year, Samsung Bioepis has reported two lots of positive analysis involving its Byooviz biosimilar, at the same time as it disclosed the findings of a five-year follow-up study for its trastuzumab biosimilar, Ontruzant.

Related Content

Topics

UsernamePublicRestriction

Register

GB151246

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel